Clinical Trials Logo

Clinical Trial Summary

Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.


Clinical Trial Description

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by NOTCH3 gene mutations, is the most frequent monogenic type of hereditary cerebral small vessel disease (CSVD). The unique pathophysiological mechanisms that small vessel disorders in CADASIL are caused by genetic mutations and that the majority of patients do not combine cerebrovascular disease risk factors make CADASIL an ideal model for studying CSVD, and the imaging findings on CADASIL can be used to diagnose and investigate the etiology of CSVD. While abnormalities in the cerebrovascular structure and hemodynamics have been well demonstrated in CADASIL, the abnormality of the BBB remains controversial. One DCE-MRI study suggested an increase in BBB permeability to gadolinium contrast in CADASIL, whereas no abnormality of BBB was found in subsequent studies in mouse models and patients. The aim of this study was to assess whether BBB function is abnormal in patients with CADASIL using DP-pCASL, which is more sensitive to subtle changes in the BBB compared to DCE-MRI. The investigators hypothesized that the BBB water exchange rate (kw) is reduced in patients with CADASIL compared to controls as assessed by DP-pCASL and that the degree of reduction in BBB water exchange rate correlates with the severity of disease in patients with CADASIL. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05902039
Study type Observational
Source Peking University First Hospital
Contact Chen Ling, PhD
Phone +86 18101358135
Email lnyy.chen@foxmail.com
Status Recruiting
Phase
Start date April 1, 2021
Completion date April 1, 2026

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Recruiting NCT05755997 - CERebrolysin In CADASIL Phase 2
Recruiting NCT06148051 - AusCADASIL: An Australian Cohort of CADASIL
Recruiting NCT04310098 - CADASIL Registry Study
Completed NCT01114815 - Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) N/A
Recruiting NCT05677880 - Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
Recruiting NCT02795052 - Neurologic Stem Cell Treatment Study N/A
Completed NCT02837354 - The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? N/A
Recruiting NCT01361763 - Safety Study of Dabigatran in CADASIL Phase 2
Completed NCT02071784 - Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Completed NCT06072118 - Adrenomedullin for CADASIL Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT05473637 - Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Enrolling by invitation NCT02032225 - Generation of a Cellular Model of CADASIL From Skin Fibroblasts N/A
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Active, not recruiting NCT04658823 - Efficacy and Safety of Tocotrienols in CADASIL Phase 2
Withdrawn NCT04334408 - Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Phase 2
Recruiting NCT05734378 - Prognosis of Cerebral Small Vessel Disease
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center
Recruiting NCT04036084 - Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy